Type 2 Diabetes in Kenya: Prevalence, Diagnosis and Treatment Pathways

Type 2 diabetes is one of Kenya's fastest-growing chronic conditions and a central concern of the national non-communicable disease (NCD) agenda. Driven by urbanisation, dietary change, sedentary lifestyles, an ageing population and rising obesity, the disease now sits alongside hypertension and cancer as one of the three NCDs that the Ministry of Health treats as strategic priorities. Type 2 diabetes is not the same as type 1 diabetes, which has its own programme priorities, but it shares the same long-term complications: damage to the eyes, kidneys, nerves, heart and blood vessels. Understanding how prevalent it is in Kenya, how it is diagnosed in clinical practice, what treatment looks like at primary-care level and how it is financed under the Social Health Authority is essential for patients, families and the diaspora community that often subsidises chronic-disease care for relatives at home.

How Common Is Type 2 Diabetes in Kenya?

The most authoritative population figures come from the 2015 Kenya STEPwise Survey for NCD Risk Factors, conducted jointly by the Ministry of Health, the Kenya National Bureau of Statistics and the World Health Organization. The survey reported a 3.1 percent adult prevalence of type 2 diabetes overall, with prevalence in women (2.8 percent) slightly higher than in men (2.0 percent) and substantially higher in urban areas (3.4 percent) than in rural areas (1.9 percent). Wealth-quintile analysis showed urban higher-income groups carrying disproportionately heavy disease burden, with prevalence in the top quintile reaching 5.2 percent, more than three times the lowest quintile. Pre-diabetes—blood-glucose levels above the normal range but below diabetes thresholds—was even more prevalent. Authoritative national-level data is available from the Kenya National Bureau of Statistics and from the Ministry of Health. Modelling exercises by the International Diabetes Federation suggest that the real prevalence in 2025 is meaningfully higher, particularly in Nairobi, Mombasa and Kisumu.

The Awareness and Treatment Gap

The most uncomfortable finding from the STEPS work was not the prevalence number but the awareness and control numbers. Only 44 percent of Kenyans with type 2 diabetes were aware of their diagnosis. Of those who were aware, only 20 percent were on treatment. And of those who were on treatment, more than half had poor glycaemic control, defined as fasting plasma glucose persistently above target ranges or HbA1c above 7 percent. Only about 7 percent of all people living with type 2 diabetes in Kenya had blood glucose under control. That cascade of leaks—undiagnosed, untreated, poorly controlled—is the precise problem the NCD Strategic Plan 2021–2026 is built to solve.

Diagnosis in Kenyan Clinical Practice

In line with the National Clinical Guidelines for Management of Diabetes Mellitus (the current version is the 2024 fifteenth edition), diagnosis in Kenya rests on one of four criteria: fasting plasma glucose at or above 7.0 mmol/L, two-hour plasma glucose at or above 11.1 mmol/L on a standard 75 g oral glucose tolerance test, random plasma glucose at or above 11.1 mmol/L with classic hyperglycaemia symptoms, or an HbA1c at or above 6.5 percent. In practice, fasting plasma glucose remains the most widely used initial test at level-3 and level-4 facilities, with HbA1c reserved for monitoring and for situations where a single confirmatory test is needed. Point-of-care glucometers are widely available and capillary blood-glucose screening is increasingly bundled into hypertension screening at health centres.

Treatment Pathways

The standard first-line treatment for newly diagnosed type 2 diabetes in Kenya is metformin, typically titrated up to 1,000 mg twice a day, supported by structured lifestyle counselling on diet, physical activity and weight management. Sulphonylureas, primarily glibenclamide and gliclazide, remain widely used as second-line agents because of their availability and low cost. Newer agents—SGLT2 inhibitors such as empagliflozin and dapagliflozin, DPP-4 inhibitors and GLP-1 receptor agonists—are increasingly prescribed in private practice and in level-5 and level-6 hospitals, particularly in patients with cardiovascular or kidney disease, but cost and supply chain are still meaningful constraints. Insulin remains essential for many patients with type 2 diabetes, particularly when oral therapies fail, during illness and surgery, and in pregnancy.

Insulin and Medicines Access

Access to insulin has improved considerably over the past decade. A landmark public-private partnership with the World Diabetes Foundation and other partners increased the number of public facilities stocking insulin from 53 in 2012 to 184 in 2015, with further expansion since. Even so, supply still varies by county and many patients still pay out of pocket at retail pharmacies. The Kenya Medical Supplies Authority is the primary distribution channel for the public sector and publishes catalogues that include insulin and oral hypoglycaemic agents on the KEMSA portal. The Pharmacy and Poisons Board, which regulates pharmaceuticals, maintains a registry of approved diabetes medicines on the Pharmacy and Poisons Board website. National policy includes longer-term plans for local insulin manufacturing to reduce import dependence.

The NCD Strategic Plan and Primary Health Care

The National NCD Prevention and Control Strategic Plan 2021–2026 is the policy backbone of the Ministry's response. It moves the centre of gravity for diabetes from referral hospitals to primary health care, supported by community health promoters, who screen for diabetes risk during household visits and refer suspected cases to a primary care provider. At the same time, the Ministry of Health is rolling out integrated NCD clinics that bundle diabetes, hypertension and cardiovascular care, which is more efficient than separate vertical clinics and matches the reality that most patients with type 2 diabetes also have raised blood pressure.

Financing Under the Social Health Authority

Until late 2024, the National Hospital Insurance Fund was the dominant single source of structured financing for chronic-disease care in Kenya. The Social Health Authority replaced it under the Social Health Insurance Act, with three funds: the Primary Healthcare Fund, the Social Health Insurance Fund and the Emergency, Chronic and Critical Illness Fund. For type 2 diabetes patients, the most important shift is that primary health care—including diabetes screening, education and medication refill at level-2 and level-3 facilities—is to be paid from the Primary Healthcare Fund. Hospitalisation for diabetic ketoacidosis, complications and specialist outpatient visits are covered by the Social Health Insurance Fund subject to the prescribed benefits package, while end-stage complications such as dialysis are covered under the Emergency, Chronic and Critical Illness Fund. The most current information is on the Social Health Authority portal.

Living With Type 2 Diabetes in Kenya

For patients, the daily reality of type 2 diabetes management in Kenya rests on a small set of habits: routine fasting and post-prandial glucose monitoring, a steady weekly walking or other moderate-intensity exercise regimen, a moderated-carbohydrate diet that nonetheless accommodates traditional staples, eye examinations at least annually, foot examinations at every clinical contact, urine protein screening for early kidney disease, and lipid profile and blood pressure control. The Kenya Diabetes Management and Information Centre and the Diabetes Kenya Association provide patient education and peer support. For Kenyans in the diaspora supporting older parents and relatives, the most useful interventions are usually paying for a structured monthly clinic visit, sponsoring a glucometer with test strips, ensuring foot inspection and footwear advice, and topping up the supply of medicines that are intermittently stocked at local public facilities.

What Comes Next

Kenya's diabetes story over the next decade will be shaped by how successfully primary health care is reorganised around chronic disease, how steadily insulin and modern oral therapies become affordable through SHA and through local manufacturing, and how rapidly community health promoters and county governments scale screening into the general adult population. The single most important household-level action is also the simplest: knowing your fasting blood-glucose number. The cheapest and most effective intervention in Kenyan diabetes today remains earlier diagnosis, before complications take hold.